Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 50 Prostatic Neoplasms 23 Lung Neoplasms 17 Breast Neoplasms 16 Squamous Cell Carcinoma of Head and Neck 13 Neoplasms 9 Stomach Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Neoplasm Metastasis 6 Head and Neck Neoplasms 6 Carcinoma, Transitional Cell 6 Urinary Bladder Neoplasms 5 Triple Negative Breast Neoplasms 5 Non-Muscle Invasive Bladder Neoplasms 5 Endometrial Neoplasms 5 Carcinoma, Squamous Cell 5 Prostatic Neoplasms, Castration-Resistant 4 Oropharyngeal Neoplasms 4 Small Cell Lung Carcinoma 3 Ovarian Neoplasms 3 Nasopharyngeal Carcinoma 3 HER2-positive Breast Cancer 3 Esophageal Squamous Cell Carcinoma 3 Carcinoma 3 Anatomic Stage I Breast Cancer AJCC v8 3 Adenocarcinoma 3 Vaccinia 2 Solid Tumors 2 Sarcoma 2 Salivary Gland Neoplasms 2

Interventions

pembrolizumab 2 erdafitinib 2 Gemcitabine 2 Cisplatin 2 Carboplatin 2 vinflunine 1 tremelimumab 1 enfortumab vedotin 1 durvalumab 1 atezolizumab 1 Tiragolumab 1 Midazolam 1 Metformin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Urothelial Cancer × Docetaxel × 90 days × Clear all

NCT03390504 2026-05-11

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting

629 enrolled 32 charts

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡